NCT06917482View on ClinicalTrials.gov

A Study to Assess the Safety and Effects of the Investigational Drug BW-40202 in Healthy Volunteers

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

December 31, 2026

Conditions
Healthy Volunteers Only
Interventions
DRUG

BW-40202 injection

BW-40202 is a conjugate drug, dosage form is solution for injection and route of administration is subcutaneous injection

OTHER

Sodium Chloride

Placebo (sodium chloride injection) will be administered as Subcutaneous injection

Trial Locations (2)

3004

NOT_YET_RECRUITING

Nucleus Network Pty Ltd, Melbourne

4006

RECRUITING

Q-Pharm Pty Ltd., Brisbane

All Listed Sponsors
lead

Shanghai Argo Biopharmaceutical Co., Ltd.

INDUSTRY